Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Cyclopharm Limited ( (AU:CYC) ).
Cyclopharm Limited has partnered with Western University in Canada to explore the use of its Technegas® technology in detecting mild to moderate asthma in young adults. The clinical trial, led by Professor Grace Parraga, aims to determine if Technegas® can identify hidden lung ventilation issues in asthma patients, potentially changing clinical practices and expanding the use of Technegas® beyond its current applications. This research aligns with Cyclopharm’s strategy to broaden the clinical use of Technegas® and represents a significant growth opportunity for the company.
The most recent analyst rating on (AU:CYC) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.
More about Cyclopharm Limited
Cyclopharm Limited is an ASX-listed radiopharmaceutical company that provides nuclear medicine solutions to improve patient care outcomes. The company’s core product, Technegas®, is used in functional lung ventilation imaging and is widely utilized in diagnosing pulmonary embolism and other respiratory conditions across 66 countries.
Average Trading Volume: 81,000
Technical Sentiment Signal: Sell
Current Market Cap: A$83.35M
Learn more about CYC stock on TipRanks’ Stock Analysis page.